Targeted antiestrogens for the prevention of breast cancer

Oncology Research

Volumn 11, Issue 9, 1999, Pages 401-407

  Bentrem, David J ^a   Craig Jordan, V ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antiestrogens; Breast cancer; Raloxifene; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST TUMOR; CLINICAL TRIAL; FEMALE; FORECASTING; HUMAN; METABOLISM; REVIEW;

BREAST NEOPLASMS; CLINICAL TRIALS; ESTROGEN RECEPTOR MODULATORS; FEMALE; FORECASTING; HUMANS; RALOXIFENE; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 0033288007     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Byers, T.; Mouchawar, J.; Marks, J.; Cady, B.; Lins, N.; Swanson, G.; Bal, D.; Eyre, H. The American Cancer Society challenge goals. Cancer 86:715-727; 1999.
2. Furr, B. J. A.; Jordan, V. C. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther. 25:127-205; 1984.
3. MacGregor, J. I.; Jordan, V. C. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 50:151-196; 1998.
4. Kedar, R. P.; Bourne, T. H.; Powles, T. J.; Collins, W. P.; Ashley, S. E.; Cosgrove, D. O.; Campbell, S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 343:1318-1321; 1994.
5. Jordan, V. C.; Fritz, N. F.; Tormey, D. C. Long-term adjuvant therapy with tamoxifen: Effects on sex hormone binding globulin and antithrombin III. Cancer Res. 47:4517-4519; 1987.
6. Stewart, P. J.; Stern, P. H. Effects of antiestrogens, tamoxifen, and clomiphene on bone résorption in vitro. Endocrinology 118: 125-131; 1986.
7. Love, R. R.; Mazess, R. B.; Barden, H. S.; Epstein, S.; Newcomb, P. A.; Jordan, V. C.; Carbone, P. P.; De Mets, D. L. Effects of tamoxifen on bone mineral density in poslmenopausal women with breast cancer. N. Engl. J. Med. 326:885-886; 1992.
8. Kristensen, B.; Ejlertsen, B.; Dolgard, P.; Larson, L.; Holmegaard, S. N.; Transbol, I.; Mouridesen, H. T. Tamoxifen and bone metabolism in postmenopausal low risk breast cancer patients: A randomized study. J. Clin. Oncol. 12:992-997; 1994.
9. Love, R. R.; Wiebe, D. A.; Feyzi, J. M.; Newcomb, P. A.; Chappell, R. J. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J. Natl. Cancer Inst. 86:1534-1539; 1995.
10. Rossner, S.; Wallgren, A. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 52: 339-346; 1984.
11. Love, R. R.; Wiebe, D. A.; Newcomb, P. A.; Cameron, L.; Leventhal, H.; Jordan, V. C; Feyzi, J.; DeMets, D. L. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann. Intern. Med. 115:860-864; 1991.
12. Assikis, V. J.; Jordan, V. C. Gynecological effects of tamoxifen and the association with endometrial cancer. Int. J. Gynecol. Obstet. 49:241-257; 1995.
13. Goldstein, S. R. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am. J. Obstet. Gynecol. 170:447-451; 1994.
14. Decensi, A.; Fontana, V.; Bruno, S.; Gustavino, C; Gatteschi, B.; Costa, A. Effect of tamoxifen on endometrial proliferation. J. Clin. Oncol. 14:434-440; 1996.
15. Fisher, B.; Constantino, J.; Wickerham, D.; Redmond, C.; Kavannah, M.; Vogel, V.; Robidoux, A.; Dimitrov, N.; Atkins, J.; Daly, M.; Wieand, S.; Tan-chiu, E.; Ford, L.; Wolmark, N. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-l study. J. Natl. Cancer Inst. 90:1371-1388; 1998.
16. Fisher, B.; Costantino, J. P.; Redmond, C. K.; Fisher, E. R.; Wickerham, D. L.; Cronin, W. M. Endometrial cancer in tamoxifen treated breast cancer patients. J. Natl. Cancer Inst. 86:527-537; 1994.
17. Early Breast Cancer Trialists' Collaborative Group. The effects of adjuvant tamoxifen and of cytotoxic chemotherapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women. N. Engl. J. Med. 319:1681-1692; 1998.
18. Powles, T. J.; Eeles, R.; Ashley, S. E.; Easton, D.; Chang, J.; Dowsett, M.; Tidy, V. A.; Viggers, J.; Davey, J. B. Interim analysis of the incident breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 362:98-101; 1998.
19. Veronesi, U.; Maisonneuve, P.; Costa, A.; Sacchini, V.; Maltoni, C.; Robertson, C.; Rotmensz, N.; Boyle, P. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomized trial among hysterectomized women. Lancet 362:93-97; 1998.
20. Black, L. J.; Jones, C. D.; Clark, J. H.; Clemens, J. A. LY156758: A unique antiestrogen displaying high affinity for estrogen receptors, negligible estrogenic activity, and nearly total estrogen antagonism in vivo. Breast Cancer Res. Treat. 2:279; 1982.
21. Black, L. J.; Jones, C.-D.; Falcone, J. F. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci. 26:1453-1458; 1983.
22. Lemer, L. J.; Jordan, V. C. Development of antiestrogens and their use in breast cancer. Cancer Res. 50:4177-4189; 1990.
23. Clemens, J. A.; Bennett, D. R.; Black, L. J.; Jones, C. D. Effects of new antiestrogen keoxifene LY156758 on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci. 32:2869-2875; 1983.
24. Anzano, M. A.; Peer, C. W.; Smith, J. M.; Müllen, L. T.; Shrader, M. W.; Logsdon, D. L.; Driver, C. L.; Brown, C. C.; Roberts, A. B.; Spom, M. B. Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid. J. Natl. Cancer Inst. 88:123-125; 1996.
25. Gottardis, M. M.; Jordan, V. C. The antitumor action of keoxifene and tamoxifen in the N-nitrosomethylurea induced rat mammary carcinoma model. Cancer Res. 47:4020-4024; 1987.
26. Poulin, R.; Merand, Y.; Poirier, D.; Levesque, C.; Dufour, J.; Labrie, F. Antiestrogenic properties of keoxifene, trans 4-hydroxytamoxifen and ICI 164,380, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells. Breast Cancer Res. Treat. 14:65-76; 1989.
27. Jiang, S. Y.; Parker, C. J.; Jordan, V. C. A model to describe how a point mutation of the estrogen receptor alters the structure function relationship of antiestrogens. Breast Cancer Res. Treat. 26: 139-147; 1993.
28. Black, L. J.; Sato, M.; Rowley, E. R.; Magee, D. E.; Bekele, A.; Williams, D. C.; Cullinan, G. J.; Bendele, R.; Kaufman, R. F.; Bensch, W. R.; Frolik, C. A.; Termine, J. D.; Bryant, H. U. Raloxifene (LY139 481 HC1) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 93:63-69; 1994.
29. Frolick, C. A.; Bryant, H. U.; Black, E. C.; Magee, D. E.; Chandrasekhar, S. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: Effects of raloxifene HCI, tamoxifen, estrogen and alendronate. Bone 18:621-627; 1996.
30. Sato, M.; McClintock, C.; Kim, J.; Turner, C. H.; Bryant, H. U.; Magee, D.; Slemenda, C. W. Dual energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J. Bone Miner. Res. 9:715-724; 1994.
31. Sato, M.; Kim, J.; Short, L. L.; Slemenda, C. W.; Bryant, H. U. Longitudinal and cross sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J. Pharmacol. Exp. Ther. 272:1252-1259; 1995.
32. Sato, M.; Bryant, H. U.; Iverson, P.; Heiterbrand, J.; Smietana, F.; Bemis, K.; Higgs, R.; Turner, C. H.; Owar, I.; Takano, Y.; Burr, D. B. Advantage of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long tdrm dosing of ovariectomized rats. J. Pharmacol. Exp. Ther. 279:298-305; 1996.
33. Turner, C. H.; Sato, M.; Bryant, H. U. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 135:2001-2005; 1994.
34. Delmas, P. D.; Bjarnason, N. H.; Mitlak, B. H.; Ravoux, A.; Shah, A. S.; Huster, W. J., Draper, M. W.; Christiansen, C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337:1641-1647; 1997.
35. Ettinger, B.; Black, D. M.; Mitlak, B. H. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 282:637-645; 1999.
36. Draper, M. W.; Flowers, D. E.; Huster, W. J.; Neild, J. A.; Harper, K. D.; Amaud C. A controlled trial of raloxifene (LY 139,481) HCI: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone Miner. Res. 11:835-842; 1996.
37. Heaney, R. P.; Draper, M. W. Raloxifene and estrogen: Comparative bone remodeling kinetics. J. Clin. Endocrinol. Metab. 82: 3425-3429; 1997.
38. Bjamason, N. H.; Haarbo, J.; Byrjalsen, I.; Kauffman, R. F.; Christiansen, C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized cholesterol fed rabbits. Circulation 96: 1964-1969; 1997.
39. Clarkson, T. B.; Anthony, M. S.; Jerome, C. P. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J. Clin. Endocrinol. Metab. 83:3001-3004; 1998.
40. Black, L. J.; Goode, R. L. Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice. Life Sci. 26:1453-1458; 1980.
41. Jordan, V. C.; Gosden, B. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogcn LY117018. Endocrinology 113:463-468; 1983.
42. Jordan, V. C.; Gosden, B. Differential antiestrogen action in the immature rat uterus: A comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor. J. Steroid Biochem. 19:1249-1258; 1983.
43. Grese, T. A.; Cho, S.; Finley, D. R.; Godfrey, A. G.; Jones, C. D.; Lugar, C. W.; Martin, M. J.; Matsumoto, K.; Pennington, L. D.; Winter, M. A.; Adrian, M. D.; Cole, H. W.; Nagee, D. E.; Phillips, D. L.; Rowley, E. R.; Short, L. L.; Glasebrook, A. L.; Bryant, H. U.; Kauffman, R. F.; Iverson, P.; Cox, D. A.; Mitlack, B. H.; Heath, H. Structure-activity relationships of selective estrogen receptor modulators: Modifications to the 2-arylbenzothiophene core of raloxifene. J. Med. Chem. 40:146-167; 1997.
44. Grese, T. A.; Sluka, J. P.; Bryant, H. U.; Cullinan, G. J.; Glasebrook, A. L.; Jones, C. D.; Matsumoto, K.; Palkowitz, A. D.; Sato, M.; Termine, J. D.; Winter, M. A.; Yang, N.; Dodge, J. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc. Natl. Acad. Sci. USA 94:14105-14110; 1997.
45. Boss, S. M.; Huster, W. J.; Neild, J. A.; Giant, M. D.; Eisenhut, C. C.; Draper, M. W. Effect of raloxifene hydrochloride on the endometrium of postmenopausal women. Am. J. Obstet. Gynecol. 177:1458-1464; 1997.
46. Jordan, V. C.; Glusman, J. E.; Eckert, S.; Lippman, M. E.; Powles, T. J.; Costa, A.; Morrow, M.; Norton, L. Incident primary breast cancers are reduced by raloxifene: Integrated data from multicenter double blind, randomized trials in 12,000 postmenopausal women. Proc. ASCO 122:466; 1998.
47. Jordan, V. C; Glusman, J. E.; Eckert, S.; Lippman, M. E.; Powles, T. J.; Costa, A.; Morrow, M.; Norton, L. Raloxifene reduces incident primary breast cancers. Integrated data from multicenter double blind, placebo controlled randomized trials in postmenopausal women. Breast Cancer Res. Treat. 50:227; 1998.
48. Gottardis, M.; Ricchio, M.; Satyaswaroop, P.; Jordan, V. C. Effect of steroidal and non steroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa 101) in athymic mice. Cancer Res. 50:3189-3192; 1990.
49. Cummings, S.; Eckert, S.; Krueger, K.; Grady, D.; Powles, T. J.; Cauley, J.; Bjamason, N.; Morrow, M.; Lippman, M. E.; Black, D.; Glusman, J.; Costa, A.; Jordan, V. C. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 281: 2189-2197; 1999.
50. Green, S.; Walter, P.; Kumar, V.; Krust, A.; Bornett, J. M.; Argos, P.; Chambon, P. Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-A. Nature 320:134; 1986.
51. Greene, G. L.; Gilna, P.; Waterfield, M.; Baker, A.; Hort, Y.; Shine, J. Sequence and expression of human estrogen receptor complementary DNA. Science 231:1150; 1986.
52. Mosselman, S.; Polman, J.; Dijkema, R. ER beta: Identification and characterization of a novel human estrogen receptor. FEES Lett. 392:49; 1996.
53. Enmark, E.; Pelto-Huikko, M.; Grandieri, K.;'Lagercrantz, S.; Lagercrantz, J.; Fried, G.; Nordenskjold, M.; Gustafsson, J. A. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J. Clin. Endocrinol. Metab. 82:4258; 1997.
54. Couse, J. F.; Curtis, S. W.; Washburn, T. F.; Lindzey, J.; Golding, T. S.; Lubahn, D. B.; Smithies, O.; Korach, K. S. Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption of the estrogen receptor gene. Mol. Endocrinol. 9:1441; 1995.
55. Kumar, V.; Green, S.; Stack, G.; Berry, M.; Jin, J. R.; Chambon, P. Functional domains of the human estrogen receptor. Cell 51: 941; 1987.
56. Metzger, D.; AH, S.; Boraert, J. M.; Chambon, P. Characterization of the amino-terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells. J. Biol. Chem. 270:9535; 1995.
57. Beato, M.; Sanchez-Pacheco, A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr. Rev. 17:587; 1996.
58. L'Horset, F.; Dauvois, S.; Heery, D. M.; Cavailles, V.; Parker, M. G. RIP-140 interacts with multiple nuclear receptors by means of two distinct sites. Mol. Cell. Biol. 16:6029; 1996.
59. Kraus, W. L.; Mclnemcy, E. M.; Katzenellenbogen, B. S. Ligand-dependent, transcriptionally productive association of the aminoand carboxy-terminal regions of a steroid hormone nuclear receptor. Proc. Natl. Acad. Sci. USA 92:12314-12318; 1995.
60. Pace, P.; Tayler, J.; Suntharalingam, S.; Coombes, R. C.; Ali, S. Human estrogen receptor βbinds DNA in a manner similar to and dimerizes with estrogen receptor a. J. Biol. Chem. 272:25832-25838; 1997.
61. Paech, K.; Webb, P.; Kuiper, G. Differential ligand activation of estrogen receptors ERcc and ERβ at AP-1 sites. Science 277: 1508-1510; 1997.
62. Ke, H. Z.; Paralkar, V. M.; Grasser, W. A. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus, and body composition in rat models. Endocrinology 139:2068-2076; 1998.
63. Rosati, R. L.; Da Suva, J. P.; Cameron, K. O. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J. Med. Chem. 41:2928-2931; 1998.
64. Willson, T. M.; Henke, B. R.; Momtahen, T. M.; Charifson, P. S.; Batchelor, K. W.; Lubahn, D. B.; Moore, L. B.; Oliver, B. B.; Sauls, H. R.; Triantafillou, J. A. 3-(4-(l,2-Diphenylbut-l-enyl)phenyl)acrylic acid: A non-steroidal estrogen with functional selectivity for bone over uterus in rats. J. Med. Chem. 37:1550-1552; 1994.
65. Willson, T. M.; Morris, J. D.; Wagner, B. L. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology 138:3901-3911; 1997.
66. Wijayaratne, A. L.; Nagel, S. C.; Paige, L. A.; Christensen, D. J.; Morris, J. D.; Fowlkes, D. M.; McDbnnell, D. P. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 140:5828-5840; 1999.
67. Gauthier, S.; Caron, B.; Cloutier, J. (S)-(+)-(4-(7-(2,2-dimethyl-loxopropoxy)-4-methyI-2-(4-(2-( 1 -piperidinyl)ethoxy)phenyl)-2Hl-benzopyran-3-yl)phenyl)-2,2-dimethylpropanoate (EM-800): A highly potent, specific and orally active non-steroidal antiestrogen. J. Med. Chem. 40:2117-2122; 1997.
68. Luo, S.; Labrie, C.; Belanger, A.; Candas, B.; Labrie, F. Prevention of development of dimethylbenz(a)anthracene (DMBA) induced-mammary tumors in the rat by the new nonsteroidal antiestrogen EM800 (Sch57050). Breast Cancer Res. Treat. 49:1-11; 1998.
69. Martel, C.; Labrie, C.; Belanger, A.; Gauthier, S.; Merand, Y.; Li, X.; Provencher, L.; Candas, B.; Labrie, F. Comparison of the effects of the new orally active antiestrogen EM-800 with ICI 182 780 and toremifene on estrogen-sensitive parameters in the ovariectomized mouse. Endocrinology 139:2486-2492; 1998.
70. Couillad, S.; Gutman, M.; Labrie, C.; Belanger, A.; Landas, B.; Labrie, F. Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res. 58:60-64; 1998.
71. MacGregor, J. I.; Liu, H.; Tonetti, D. A.; Jordan, V. C. The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 with the human estrogen receptor (ER). Cancer Res. 59: 4308-4313; 1999.
72. Levenson, A. S.; Jordan, V. C. Selective oestrogen receptor modulation: Molecular pharmacology for the millennium. Eur. J. Cancer 35:1628-1639; 1999.
73. Couse, J. F.; Korach, K. S. Estrogen receptor null mice: What have we learned and where will they lead us? Endocr. Rev. 20: 358-417; 1999.
74. Brzozowski, A. M.; Pike, A. C.; Dauter, Z.; Hubbard, R.; Bonn, T.; Engstrom, O.; Ohman, L. Molecular basis of agonism and antagonism in the estrogen receptor. Science 389:753-758; 1997.
75. Pike, A.; Brzozowski, A. M.; Hubbard, R. E.; Bonn, T.; Thorseil, A.; Engstrom, O.; Ljunggren, J.; Gustafsson, J.; Carlquist, M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 18:4608-4618; 1999.